A pentavalent inhibitor for cholera toxin
Research reports the first pentavalent inhibitor for cholera toxin that exactly matches the pentavalent structure of the cholera toxin binding domain.
Cholera still represents a serious health problem in areas of the developing world where there is a lack of clean water and proper sanitation. It causes an acute intestinal infection that in severe cases can be fatal.
An international collaboration of scientists developed an inhibitor based on the pentasaccharide GM1, which is the natural target ligand for the cholera toxin on cellular membranes of the infected hosts’ intestinal epithelial surface. Previous work has combined either pentavalent scaffolds with simpler sugars, or non-pentavalent scaffolds with GM1, but this is the first example of an inhibitor that is both pentavalent and uses the natural ligand for cholera toxin.
The scientists synthesised the inhibitor via enzymatic synthesis of GM1 and coupling to a calix[5]arene scaffold. Tests to determine the potency of the inhibitor showed it to have the highest relative inhibitory potency documented for cholera toxin inhibitors so far.
Other news from the department science
These products might interest you

Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes

Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates

Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"

Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures

Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency

Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Affimed joins the Molecular Imaging Technology Initiative - BMBF awards Affimed a funding grant of €550K
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research

Revolutionary Breakthrough: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing Genes - Scientists demonstrate the therapeutic value of a compound that inhibits oncogene translation

In slow motion against antibiotic resistance - How novel therapeutics provide insight into bacteria membranes

How the Brain Reacts to Sleep Deprivation

Texas A&M research aims to improve Lyme disease diagnostics - Scientists are testing Raman spectroscopy as a diagnostic tool for Lyme disease
BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401)
Roche and the Department of Health of Junta de Andalucía Collaborate in Spanish Medical Genome Project

Seeing memories being made
Glycotope received regulatory approval for glycooptimized and fully human glycosylated antibody CetuGEX
